Bulk supply Dofetilide CAS No.115256-11-6 CAS NO.115256-11-6

1.We supply our existing products steadily and provide continuous and perfect aftersales service to help our customers solve all kinds of questions during the process of using the products.

2.We pay close attention to the international and domestic market trends constantly, enriching the latest products reserve for future use to provide customers with more updated .

3.We continue to research and practice to improve product performances to make our products more in line with customer application requirements.

4.We also provide full customize service such as research and develop, laboratorysmall-scale trial test, scale up production and cost accounting according to the chemical structure, quantityand quality requirements provided by our customers.

1. the most competitive prise

2. the best quality

3. efficient service

4. the best package

Dofetilide was launched in the US as a novel class III antiarrhythmic for treatment of cardiac patients with highly symptomatic atrial fibrillation This bisarylsulfonamide can be obtained by a three step synthesis starting from 4-nitro-N-methylphenethylamine and involving simultaneous nitro reduction and mesylation on both aromatic amine functions. In contrast to other class III antiarrhythmic agents such as amiodarone, dofetilide potently and selectively inhibits a single potassium channel, Ikr, the rapidly acting component of the delayed rectifier potassium current, Accordingly, by blocking the open state of Ikr, dofetilide is able to prolong the effective refractory period (ERP) in both atrial and ventricular myocardium and the monophasic action potential duration. Moreover, as it targets only one cardiac ion channel, it does not produce any effects on the sinus node, cardiac conduction system and other extracardiac organs, making it unique among established class III agents. Several pharmacological studies with models using different animal species indicated that dofetilide was a potent and highly selective class III antiarrhythmic agent devoid of cardiodepressive effects. During clinical trials in patients with paroxysmal atrial or supraventricular fibrillation, dofetilide was found to increase atrial and ventricular refractory periods without affecting conduction or sinus node function. If increases in the QT/QTc interval after oral or intravenous dofetilide are expected, as for other class III antiarrhythmic agents, other electrocardiographic intervals are unaffected.